Novel immunotherapeutic approaches for pediatric classical Hodgkin lymphoma: Nivolumab or brentuximab vedotin with the AVD regimen.

Okeleji, Olayinka; Gibson, Amber; Nunez, Cesar; Garcia, Miriam B; Roth, Michael; Cuglievan, Branko; McCall, David

Okeleji, Olayinka; Gibson, Amber; Nunez, Cesar; Garcia, Miriam B; Roth, Michael; Cuglievan, Branko; McCall, David.

Affiliation

Okeleji O; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Gibson A; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Nunez C; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Garcia MB; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Roth M; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Cuglievan B; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
McCall D; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Pediatr Blood Cancer ; 71(8): e31091, 2024 Aug.

Article de En | MEDLINE | ID: mdl-38840433

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Maladie de Hodgkin / Protocoles de polychimiothérapie antinéoplasique / Nivolumab / Brentuximab védotine Limites: Adolescent / Child / Female / Humans / Male Langue: En Journal: Pediatr Blood Cancer Sujet du journal: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Année: 2024 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google